Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

rs73185306 C/T is not a predisposing risk factor for inherited chromosomally-integrated human herpesvirus 6A/B.

Mouammine A, Gravel A, Dubuc I, Feroz Zada Y, Provost S, Busseuil D, Tardif JC, Dubé MP, Flamand L.

J Infect Dis. 2019 Oct 17. pii: jiz527. doi: 10.1093/infdis/jiz527. [Epub ahead of print]

PMID:
31621866
2.

Inherited chromosomally integrated HHV-6 demonstrates tissue-specific RNA expression in vivo that correlates with increased antibody immune response.

Peddu V, Dubuc I, Gravel A, Xie H, Huang ML, Tenenbaum D, Jerome KR, Tardif JC, Dubé MP, Flamand L, Greninger AL.

J Virol. 2019 Oct 9. pii: JVI.01418-19. doi: 10.1128/JVI.01418-19. [Epub ahead of print]

3.

Chromatin Profiles of Chromosomally Integrated Human Herpesvirus-6A.

Saviola AJ, Zimmermann C, Mariani MP, Signorelli SA, Gerrard DL, Boyd JR, Wight DJ, Morissette G, Gravel A, Dubuc I, Flamand L, Kaufer BB, Frietze S.

Front Microbiol. 2019 Jun 26;10:1408. doi: 10.3389/fmicb.2019.01408. eCollection 2019.

4.

Effect of food deprivation on the hypothalamic gene expression of the secretogranin II-derived peptide EM66 in rat.

Trebak F, Dubuc I, Picot M, Alaoui A, Leprince J, Prévost G, Anouar Y, Magoul R, Chartrel N.

Neuroreport. 2017 Nov 8;28(16):1049-1053. doi: 10.1097/WNR.0000000000000889.

PMID:
28902709
5.

Cell Culture Systems To Study Human Herpesvirus 6A/B Chromosomal Integration.

Gravel A, Dubuc I, Wallaschek N, Gilbert-Girard S, Collin V, Hall-Sedlak R, Jerome KR, Mori Y, Carbonneau J, Boivin G, Kaufer BB, Flamand L.

J Virol. 2017 Jun 26;91(14). pii: e00437-17. doi: 10.1128/JVI.00437-17. Print 2017 Jul 15.

6.

A potential role for the secretogranin II-derived peptide EM66 in the hypothalamic regulation of feeding behaviour.

Trebak F, Dubuc I, Arabo A, Alaoui A, Boukhzar L, Maucotel J, Picot M, Cherifi S, Duparc C, Leprince J, Prévost G, Anouar Y, Magoul R, Chartrel N.

J Neuroendocrinol. 2017 Mar;29(3). doi: 10.1111/jne.12459.

PMID:
28166374
7.

Inherited Chromosomally Integrated Human Herpesvirus 6 and Breast Cancer.

Gravel A, Dubuc I, Brooks-Wilson A, Aronson KJ, Simard J, Velásquez-García HA, Spinelli JJ, Flamand L.

Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):425-427. doi: 10.1158/1055-9965.EPI-16-0735. Epub 2016 Oct 24.

8.

Inherited chromosomally integrated human herpesvirus 6 as a predisposing risk factor for the development of angina pectoris.

Gravel A, Dubuc I, Morissette G, Sedlak RH, Jerome KR, Flamand L.

Proc Natl Acad Sci U S A. 2015 Jun 30;112(26):8058-63. doi: 10.1073/pnas.1502741112. Epub 2015 Jun 15.

9.

Characterization of human herpesvirus 6A/B U94 as ATPase, helicase, exonuclease and DNA-binding proteins.

Trempe F, Gravel A, Dubuc I, Wallaschek N, Collin V, Gilbert-Girard S, Morissette G, Kaufer BB, Flamand L.

Nucleic Acids Res. 2015 Jul 13;43(12):6084-98. doi: 10.1093/nar/gkv503. Epub 2015 May 20.

10.

Neuropeptide Y and α-MSH circadian levels in two populations with low body weight: anorexia nervosa and constitutional thinness.

Galusca B, Prévost G, Germain N, Dubuc I, Ling Y, Anouar Y, Estour B, Chartrel N.

PLoS One. 2015 Mar 23;10(3):e0122040. doi: 10.1371/journal.pone.0122040. eCollection 2015.

11.

Human herpesvirus 6B immediate-early I protein contains functional HLA-A*02, HLA-A*03, and HLA-B*07 class I restricted CD8(+) T-cell epitopes.

Iampietro M, Morissette G, Gravel A, Dubuc I, Rousseau M, Hasan A, O'Reilly RJ, Flamand L.

Eur J Immunol. 2014 Dec;44(12):3573-84. doi: 10.1002/eji.201444931. Epub 2014 Oct 29.

12.

Influenza virus H1N1 activates platelets through FcγRIIA signaling and thrombin generation.

Boilard E, Paré G, Rousseau M, Cloutier N, Dubuc I, Lévesque T, Borgeat P, Flamand L.

Blood. 2014 May 1;123(18):2854-63. doi: 10.1182/blood-2013-07-515536. Epub 2014 Mar 24.

PMID:
24665136
13.

Synthesis and biological effects of c(Lys-Lys-Pro-Tyr-Ile-Leu-Lys-Lys-Pro-Tyr-Ile-Leu) (JMV2012), a new analogue of neurotensin that crosses the blood-brain barrier.

Bredeloux P, Cavelier F, Dubuc I, Vivet B, Costentin J, Martinez J.

J Med Chem. 2008 Mar 27;51(6):1610-6. doi: 10.1021/jm700925k. Epub 2008 Mar 6.

PMID:
18321036
14.

Comparisons between bupropion and dexamphetamine in a range of in vivo tests exploring dopaminergic transmission.

Bredeloux P, Dubuc I, Costentin J.

Br J Pharmacol. 2007 Mar;150(6):711-9. Epub 2007 Feb 12.

15.

Interactions between NTS2 neurotensin and opioid receptors on two nociceptive responses assessed on the hot plate test in mice.

Bredeloux P, Costentin J, Dubuc I.

Behav Brain Res. 2006 Dec 15;175(2):399-407. Epub 2006 Oct 30.

PMID:
17074405
16.

Localization of neurotensin NTS2 receptors in rat brain, using.

Asselin ML, Dubuc I, Coquerel A, Costentin J.

Neuroreport. 2001 Apr 17;12(5):1087-91.

PMID:
11303751
17.

Developmental changes of (3)H-labelled mu-opioid receptors in brainstems of intra-uterine growth-restricted rats.

Liu J, Dong C, Cazin L, Clabaut M, Dubuc I, Costentin J, Coquerel A.

Brain Res Dev Brain Res. 2001 Feb 28;126(2):211-5.

PMID:
11248355
18.

The partial agonist properties of levocabastine in neurotensin-induced analgesia.

Dubuc I, Remande S, Costentin J.

Eur J Pharmacol. 1999 Sep 17;381(1):9-12.

PMID:
10528128
19.

Identification of the receptor subtype involved in the analgesic effect of neurotensin.

Dubuc I, Sarret P, Labbé-Jullié C, Botto JM, Honoré E, Bourdel E, Martinez J, Costentin J, Vincent JP, Kitabgi P, Mazella J.

J Neurosci. 1999 Jan 1;19(1):503-10.

20.
21.

The nonpeptide neurotensin antagonist, SR 48692, used as a tool to reveal putative neurotensin receptor subtypes.

Dubuc I, Costentin J, Terranova JP, Barnouin MC, Soubrié P, Le Fur G, Rostène W, Kitabgi P.

Br J Pharmacol. 1994 Jun;112(2):352-4.

22.

In vivo and in vitro structure-activity studies with peptide and pseudopeptide neurotensin analogs suggest the existence of distinct central neurotensin receptor subtypes.

Labbé-Jullié C, Dubuc I, Brouard A, Doulut S, Bourdel E, Pelaprat D, Mazella J, Martinez J, Rostène W, Costentin J, et al.

J Pharmacol Exp Ther. 1994 Jan;268(1):328-36.

PMID:
8301574
24.

Synthesis and analgesic effects of N-[3-[(hydroxyamino) carbonyl]-1-oxo-2(R)-benzylpropyl]-L-isoleucyl-L-leucine, a new potent inhibitor of multiple neurotensin/neuromedin N degrading enzymes.

Doulut S, Dubuc I, Rodriguez M, Vecchini F, Fulcrand H, Barelli H, Checler F, Bourdel E, Aumelas A, Lallement JC, et al.

J Med Chem. 1993 May 14;36(10):1369-79.

PMID:
8496905
25.

JMV 449: a pseudopeptide analogue of neurotensin-(8-13) with highly potent and long-lasting hypothermic and analgesic effects in the mouse.

Dubuc I, Costentin J, Doulut S, Rodriguez M, Martinez J, Kitabgi P.

Eur J Pharmacol. 1992 Aug 25;219(2):327-9.

PMID:
1425958
26.

Effects of thiorphan, bestatin and a novel metallopeptidase inhibitor JMV 390-1 on the recovery of neurotensin and neuromedin N released from mouse hypothalamus.

Kitabgi P, Dubuc I, Nouel D, Costentin J, Cuber JC, Fulcrand H, Doulut S, Rodriguez M, Martinez J.

Neurosci Lett. 1992 Aug 17;142(2):200-4.

PMID:
1454216
27.

Functional and pharmacological aspects of central neuropeptidergic transmission mediated by neurotensin and neuromedin n.

Kitabgi P, De Nadai F, Labbe-Jullie C, Dubuc I, Nouel D, Costentin J, Masuo Y, Rostene W, Woulfe J, Lafortune L, et al.

Clin Neuropharmacol. 1992;15 Suppl 1 Pt A:313A-314A. No abstract available.

PMID:
1323393
29.

Calcium-dependent release of neuromedin N and neurotensin from mouse hypothalamus.

Kitabgi P, De Nadai F, Cuber JC, Dubuc I, Nouel D, Costentin J.

Neuropeptides. 1990 Feb;15(2):111-4.

PMID:
2080018
30.

Hypothermic effect of neuromedin N in mice and its potentiation by peptidase inhibitors.

Dubuc I, Nouel D, Coquerel A, Menard JF, Kitabgi P, Costentin J.

Eur J Pharmacol. 1988 Jun 22;151(1):117-21.

PMID:
3416919
31.

Potentiation by thiorphan and bestatin of the naloxone-insensitive analgesic effects of neurotensin and neuromedin n.

Coquerel A, Dubuc I, Kitaegi P, Costentin J.

Neurochem Int. 1988;12(3):361-6.

PMID:
20501239
32.

Naloxone-insensitive potentiation of neurotensin hypothermic effect by the enkephalinase inhibitor thiorphan.

Coquerel A, Dubuc I, Menard JF, Kitabgi P, Costentin J.

Brain Res. 1986 Nov 29;398(2):386-9.

PMID:
3542125
33.
34.

Behavioural data suggesting the plurality of central dopamine receptors.

Costentin J, Dubuc I, Protais P.

Adv Biochem Psychopharmacol. 1983;37:289-97. No abstract available.

PMID:
6138951
35.

Antagonism of the apomorphine-induced yawning by "atypical" neuroleptics.

Dubuc I, Protais P, Colboc O, Costentin J.

Neuropharmacology. 1982 Nov;21(11):1203-6.

PMID:
6129594

Supplemental Content

Support Center